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Should Be a Universal Standard of Care*
David J. Maron, MD,y William E. Boden, MDzA wise man, therefore, proportions his
belief to the evidence.
—David Hume (1).R ecent randomized controlled trials of man-agement strategies for patients with stableischemic heart disease (SIHD) have used
intensive pharmacological and lifestyle interven-
tions, often referred to as optimal medical therapy
(OMT), with or without initial revascularization (2–4).
Although critics and supporters alike have attributed
the lack of difference in death and myocardial infarc-
tion (MI) between treatment groups, in part, to the
high quality of OMT used in all subjects, this “claim”
has been an unproven assumption because these
trials lacked a control group that did not receive
OMT. An independent beneﬁt conferred by intensive
medical therapy has not, to date, been convincingly
established.SEE PAGE 765In this issue of the Journal, Bittner et al. (5) report a
post-hoc analysis from the BARI 2D (Bypass Angio-
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relationship between risk factor control, survival, and
the composite endpoint of death, MI, or stroke,
despite the absence of a no-OMT control group. As
previously reported, not all BARI 2D subjects ach-
ieved their risk factor goals (6); in fact, only a small
minority of patients achieved all of their treatment
targets. In the present analysis, the investigators
leveraged this spectrum of risk factor control by
aggregating both treatment groups to assess the
relationship between the degree of success with risk
factor goal attainment and clinical outcomes.
Six risk factors were used in this analysis (5),
and patients were considered “in control” if they
achieved the following: no smoking; triglycerides
<150 mg/dl; non–high-density lipoprotein cholesterol
<130 mg/dl; glycosylated hemoglobin <7%; systolic
blood pressure <130 mm Hg; and diastolic blood
pressure <80 mm Hg. With the exception of the
no-smoking goal, these trial deﬁnitions go beyond
current Class I clinical practice guideline recommen-
dations (7).
At baseline, only 7% of participants met all 6 risk
factor goals (5). At 5 years, only 15% of patients ach-
ieved control of all 6 risk factors. Nevertheless,
approximately three-quarters of patients had $4 risk
factors in control during long-term follow-up. There
was no relationship between the number of risk fac-
tors in control at baseline and subsequent death (the
BARI 2D primary endpoint). In contrast, risk factor
control at year 1 was strongly related to survival and
cardiovascular outcomes after adjusting for the
number of risk factors in control at baseline. Patients
with only 0 to 2 risk factors in control had twice the
risk of death (hazard ratio: 2.0; 95% conﬁdence in-
terval: 1.3 to 3.3; p ¼ 0.0031) and 1.7 times the risk of
the composite outcome (hazard ratio: 1.7; 95% conﬁ-
dence interval: 1.2 to 2.5; p ¼ 0.0043) compared with
patients who were able to achieve all 6 risk factors in
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775control. There was no signiﬁcant interaction between
the initial treatment assignment (prompt revascular-
ization or medical therapy) and the number of risk
factors in control for either outcome.
This report (5) is important because it has been
assumed that OMT in recent SIHD strategy trials
reduced clinical events (assumed because there were
no comparison groups that did not receive OMT), but
until now the evidence to support this assumption
has been lacking. With this analysis, although
post-hoc and exploratory, the authors illustrate the
impact of good multiple risk factor control versus
poor or moderate risk factor control in SIHD patients
with diabetes by using adjudicated endpoints. The
ﬁndings are consistent with what might be expected
on the basis of prior studies that compared aggressive
multiple risk factor intervention with usual care (8,9).
In addition, a recent publication from the SYNTAX
(Synergy Between Percutaneous Coronary Interven-
tion With TAXUS and Cardiac Surgery) trial in-
vestigators analyzed the effect of OMT in patients
with complex coronary artery disease randomized
to undergo percutaneous coronary intervention or
coronary artery bypass grafting (10). OMT, which was
not part of the trial intervention, was deﬁned as the
combination of at least 1 antiplatelet drug, statin,
beta-blocker, and angiotensin-converting enzyme
inhibitor or angiotensin receptor blocker; this is
arguably a less stringent deﬁnition than reaching 6
risk factor goals. OMT, which was used in #50% of
patients over 5 years, was associated with a 36%
relative reduction in mortality at the 5-year follow-up
compared with those not receiving OMT. The 36%
relative reduction in mortality over 5 years associated
with OMT was greater than the 26% relative reduction
in mortality over 5 years associated with the ran-
domized treatment assignment to coronary artery
bypass grafting versus percutaneous coronary inter-
vention in SYNTAX.
The present analysis (5) showed that when mul-
tiple risk factor goals were achieved in diabetic
patients with SIHD, survival was improved and
cardiovascular events were reduced, but control ofall 6 treatment targets was achieved in only a mi-
nority of patients. Simultaneous attainment of mul-
tiple risk factor goals in patients with SIHD has
previously been shown to be infrequent in the
REGARDS (Reasons for Geographic and Racial Dif-
ferences in Stroke) prospective cohort study (11) and
in a pooled analysis from COURAGE (Clinical Out-
comes Utilizing Revascularization and Aggressive
Drug Evaluation), BARI 2D, and FREEDOM (Com-
parison of Two Treatments for Multivessel Coronary
Artery Disease in Individuals With Diabetes) (6). The
remarkable observation in the present report is the
signiﬁcantly better survival (a 50% lower mortality
rate) among patients who achieved good risk factor
control in a trial that found no survival beneﬁt from
revascularization. Although the study was not a
randomized comparison of OMT versus no OMT,
the conclusions are convincing and consistent with
evidence from decades of careful epidemiological
research.
Despite the ongoing uncertainty regarding the
beneﬁt of elective revascularization in patients with
SIHD (currently being tested prospectively in the
ISCHEMIA [International Study of Comparative
Health Effectiveness with Medical and Invasive
Approaches] trial [12]), we believe these data are
compelling and argue persuasively that all patients
with SIHD should receive OMT, regardless of whether
they undergo revascularization. However, the use of
OMT remains disappointingly low in patients with
SIHD (10,13). The ﬁndings of Bittner et al. (5) provide
powerful evidence that simultaneous control of
multiple risk factors improves survival and reduces
nonfatal MI and stroke. For that singular reason, OMT
needs to be more widely embraced and utilized by
clinicians as both a best medical practice and a uni-
versal standard of care in all patients with coronary
artery disease.
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